SCHEMBL7290449

SCHEMBL7290449

O=C(Cl)CCSC(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 4/20 0.41
GSK3B P49841 2/20 0.41
MAPK1 P28482 2/20 0.41
TRPA1 O75762 1/20 0.41
HIF1A Q16665 1/20 0.41
PTPN1 P18031 1/20 0.41
GPR139 Q6DWJ6 1/20 0.41
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
LMNA P02545 1/20 0.39
NR4A2 P43354 1/20 0.39
CES1 P23141 4/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8309337 0.84 NR4A2 (0.52) KMT2AALDH1A1GSK3BMAPK1HIF1A
SCHEMBL16047247 0.83 KMT2A (0.52) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL18244312 0.82 MAPT (0.55) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL11001103 0.81 GSK3B (0.44) KMT2AALDH1A1GSK3BMAPTL3MBTL1
SCHEMBL12154245 0.81 KMT2A (0.48) KMT2AALDH1A1GSK3BMAPK1PTPN1
SCHEMBL6057430 0.80 ALDH1A1 (0.48) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL8131829 0.80 KMT2A (0.54) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL7909243 0.79 KMT2A (0.49) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL31131464 0.79 KMT2A (0.49) KMT2AALDH1A1GSK3BMAPK1TRPA1
SCHEMBL18243769 0.78 KMT2A (0.46) KMT2AALDH1A1GSK3BPTPN1GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8241829-B2 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2012-08-14 US disclosed
US-8241829-B2 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2012-08-14 US disclosed
US-8049042-B2 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2011-11-01 US disclosed
US-8049042-B2 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2011-11-01 US disclosed
US-20110144295-A1 RESIST POLYMER, RESIST COMPOSITION, PROCESS FOR PATTERN FORMATION, AND STARTING COMPOUNDS FOR PRODUCTION OF THE RESIST POLYMER MITSUBISHI RAYON CO., LTD. (JP) 2011-06-16 US disclosed
US-20110144295-A1 RESIST POLYMER, RESIST COMPOSITION, PROCESS FOR PATTERN FORMATION, AND STARTING COMPOUNDS FOR PRODUCTION OF THE RESIST POLYMER MITSUBISHI RAYON CO., LTD. (JP) 2011-06-16 US disclosed
US-20090198065-A1 RESIST POLYMER, RESIST COMPOSITION, PROCESS FOR PATTERN FORMATION, AND STARTING COMPOUNDS FOR PRODUCTION OF THE RESIST POLYMER MITSUBISHI RAYON CO., LTD. (JP) 2009-08-06 US disclosed
US-20090198065-A1 RESIST POLYMER, RESIST COMPOSITION, PROCESS FOR PATTERN FORMATION, AND STARTING COMPOUNDS FOR PRODUCTION OF THE RESIST POLYMER MITSUBISHI RAYON CO., LTD. (JP) 2009-08-06 US disclosed
US-20070190449-A1 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2007-08-16 US disclosed
US-20070190449-A1 Resist polymer, resist composition, process for pattern formation, and starting compounds for production of the resist polymer MITSUBISHI RAYON CO., LTD. (JP) 2007-08-16 US disclosed
US-4457935-A ANGIOTENSIN-CONVERTING ENZYME INHIBITOR SANTEN PHARMACEUTICAL CO., LTD. (JP) 1984-07-03 US disclosed
US-4442038-A Converting enzyme inhibitors NORWICH EATON PHARMACEUTICALS, INC. 1984-04-10 US disclosed
EP-0103927-A1 Converting enzyme inhibitors Norwich Eaton Pharmaceuticals, Inc. (US) 1984-03-28 EP disclosed
US-4430344-A Antihypertensive 4-thiazolidinecarboxylic acids SANTEN PHARMACEUTICAL CO., LTD. (JP) 1984-02-07 US disclosed
US-4423054-A Antihypertensive 4-thiazolidinecarboxylic acids (substituted alkyl derivatives) SANTEN PHARMACEUTICAL CO., LTD. (JP) 1983-12-27 US disclosed
EP-0012845-B1 TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Tanabe Seiyaku Co., Ltd. (JP) 1983-06-22 EP disclosed
US-4386096-A ANGIOTENSIN-CONVERTING ENZYME INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 1983-05-31 US disclosed
US-4356183-A ENZYME INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 1982-10-26 US disclosed
US-4264620-A HYPOTENSIVE AGENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 1981-04-28 US disclosed
EP-0012845-A1 Tetrahydroisoquinoline compounds, process for preparing same and pharmaceutical compositions containing them Tanabe Seiyaku Co., Ltd. (JP) 1980-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090198065-A1 RESIST POLYMER, RESIST COMPOSITION, PROCESS FOR PATTERN FORMATION, AND STARTING COMPOUNDS FOR PRODUCTION OF THE RESIST POLYMER CHRM1, CHRM2, PKN2 KMT2A 905/4885ALDH1A1 3349/4885GSK3B 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.